Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis

Jianfang Zhu,Ke Yuan,Sunita Rana,Satya Lavanya Jakki,Amit Subray Bhat,Li Liang,Chunlin Wang

DOI: https://doi.org/10.1038/s41598-024-58616-4

IF: 4.6

2024-04-07

Scientific Reports

Abstract:The purpose of this study is to compare the relative efficacy and safety of long-acting growth hormone (LAGH) as a growth hormone replacement therapy in prepubertal children with growth hormone deficiency (GHD). We searched the PubMed, Embase, CNKI, and Wanfang databases from inception to July 2023 and identified eleven relevant studies. PEG-LAGH showed better effect on height velocity (mean difference [MD]: − 0.031, 95% credibility interval [CrI]: − 0.278, 0.215) than somatrogon (MD: 0.105, 95% CrI: − 0.419, 0.636), somapacitan (MD: 0.802, 95% CrI: − 0.451, 2.068) and lonapegsomatropin (MD: 1.335, 95% CrI: − 0.3, 2.989) when compared with daily growth hormone (DGH). Furthermore, in terms of height standard deviation score, PEG-LAGH demonstrated better improvement (MD: − 0.15, 95% CrI: − 1.1, 0.66) than somatrogon (MD: − 0.055, 95% CrI: − 1.3, 0.51) and somapacitan (MD: 0.22, 95% CrI: − 0.91, 1.3). PEG-LAGH (risk ratio [RR]: 1.00, 95% CrI: 0.82, 1.2) reduced the risk of adverse events compared with other LAGH (somatrogon, RR: 1.1, 95% CrI: 0.98, 1.2; somapacitan, RR: 1.1, 95% CrI: 0.96, 1.4; lonapegsomatropin, RR, 1.1, 95% CrI: 0.91, 1.3) and was comparable with DGH. This is the first study to indirectly compare the LAGH thorough a network meta-analysis and provide evidence of the optimal efficacy of various LAGH specifically PEG-LAGH and acceptable safety profile in prepubertal children with GHD.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the relative efficacy and safety of long - acting growth hormone (LAGH) in the treatment of growth hormone deficiency (GHD) in children, and to indirectly compare different types of LAGH through network meta - analysis (NMA) to determine the optimal LAGH treatment regimen.

Specifically, the paper focuses on the following aspects:
1. **Efficacy evaluation**: The main evaluation indicators are height velocity (HV) and height standard deviation score (HSDS). By comparing with daily - injected growth hormone (DGH), the efficacy of PEG - LAGH, somatrogon, somapacitan and lonapegsomatropin and other LAGH is evaluated.
2. **Safety evaluation**: The incidence of adverse events (AEs) of these LAGH is evaluated, especially the safety compared with DGH.
3. **Indirect comparison**: Due to the lack of direct head - to - head comparison studies, the paper indirectly compares the efficacy and safety of different LAGH through the network meta - analysis method to provide more comprehensive evidence to support clinical decision - making.

The main findings of the paper include:
- PEG - LAGH performs better than other LAGH in increasing height velocity and height standard deviation score.
- The safety of PEG - LAGH is comparable to that of DGH and better than that of other LAGH.
- Through the surface under the cumulative ranking curve (SUCRA) value, PEG - LAGH performs well in both efficacy and safety.

In conclusion, this paper aims to provide a scientific basis for clinicians to select the optimal LAGH treatment regimen, especially in improving the treatment compliance and clinical effect of children with GHD.